Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy.
Frontiers in immunology
Liu X, Yu W, Wang Y, Xing D, Huang H, Zhu W, Sun P.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2025
Cancer Research
Immunology
No items found.
Key Finding
These findings demonstrate that epitope-guided biparatopic antibody design can enhance HER2 downregulation and restore sensitivity to HER2-targeted therapy in vitro, providing a strategy for the development of next-generation receptor-targeted biologics.
Countstar Connection
The study's cell samples underwent cell-count and viability assessment with Countstar (model not specified) during growth assessment in the 2025 Frontiers in immunology study.
